Reducar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reducar

Quick Facts

Property Description
Active Ingredient Isotretinoin (13-cis-Retinoic Acid)
Form Soft gel capsules
Pharmacological Class Systemic anti-acne agent / Retinoid
Common Purpose Resolution for severe, resistant acne
Origin Synthetic derivative of Vitamin A

Pharmacological Identity and Composition

Reducar is a potent, prescription-only medicine whose active ingredient is Isotretinoin, formally classified as a Retinoid for treatment of acne for systemic use. The substance itself is a synthetic derivative, chemically defined as 13-cis-Retinoic Acid, which is closely related to Vitamin A. As a Systemic anti-acne agent, the medication is designed to work internally to modify the underlying biological factors that cause severe and persistent forms of acne.

The medicine is supplied as a single-ingredient product in the form of soft gel capsules for oral administration. This specific formulation, utilizing an oil-based vehicle, is designed to enhance the bioavailability of the active component. Reducar, as a brand, maintains this crucial soft gel capsule form, ensuring reliable absorption of the lipophilic Isotretinoin over alternative tablet formulations.


General Purpose and Mechanism Summary

The general purpose of Reducar is to achieve a long-term resolution for forms of acne that are severe, cystic, or have proven resistant to standard treatments. It is clinically recognized for its unique ability to intervene in the complex pathology of severe acne. Isotretinoin is primarily utilized for severe acne because it targets fundamental disease mechanisms, leading to sustained remission.

It works by addressing the root causes of the condition simultaneously through two key physiological effects: a profound oil production reduction and the normalization of keratinization (skin cell shedding). By interrupting the entire acne cycle—drastically reducing the size and output of the sebaceous glands while preventing skin cell blockage—it offers the highest probability of sustained clearance and relief from the discomfort of deep, inflamed lesions.

Regulatory References

  1. Isotretinoin EMA referral procedure for systemic use
  2. NIH/NLM's MedlinePlus on Isotretinoin for severe acne

What side effects are possible with Reducar?

Possible side effects and safety information

The safety profile of Reducar (Isotretinoin) is comprehensively defined in government regulatory labeling, emphasizing both high-frequency, expected adverse reactions and several severe, systemic safety constraints.

Absolute Safety Constraint

Isotretinoin carries a Boxed Warning due to the absolute and predictable risk of severe teratogenicity (birth defects) if used during pregnancy. This mandates that the medicine is strictly contraindicated in women who are or may become pregnant and is subject to mandatory pregnancy prevention programs.

Adverse Reactions by System and Frequency

The most frequently reported adverse reactions, classified as Very Common (ge1/10) in regulatory documents, primarily affect the skin and musculoskeletal system. These include dryness of the lips (Cheilitis), generalized dry skin, arthralgia (joint pain), back pain, and elevated blood creatine kinase (CPK) levels. Common reactions (ge1/100 to <1/10) also include headache and alopecia (hair loss).

Serious Adverse Reactions

Official labeling describes several serious adverse reactions affecting multiple physiological systems. These include psychiatric disorders such as new-onset or worsening depression, psychosis, and suicidal thoughts and behavior. Other documented serious risks are Pseudotumor Cerebri (a neurological condition), acute pancreatitis, Inflammatory Bowel Disease (IBD), and severe mucocutaneous reactions like Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).

Safety-Related Restrictions

Safety notes specify that co-administration with tetracycline antibiotics must be avoided due to the increased risk of Pseudotumor Cerebri. The use of Vitamin A supplements is also restricted to prevent cumulative toxicity. The label further indicates that some effects, such as decreased night vision, may persist after treatment cessation.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the official, documented profile of Reducar overdose as presented in authoritative government regulatory sources. It is not clinical advice.

Documented Overdose Manifestations

Official regulatory documents describe that overdosage of Reducar may result in clinical manifestations that often reflect an extension of the drug's known pharmacological activity. Symptoms can include nausea, vomiting, dizziness, changes in heart rate, or altered levels of consciousness. Serious and potentially life-threatening outcomes, such as severe hepatic or cardiovascular complications, have been documented in cases of acute overdosage.

Mandatory Emergency Actions

Immediate medical attention is required in all cases of known or suspected Reducar overdose. Regulatory instructions emphasize that a Poison Control Center or emergency medical services must be contacted right away. This immediate action is necessary for all individuals, including children, even if the person does not appear to have any immediate signs or symptoms of an overdose, as toxic effects may be delayed.

Official Management Strategy

Management procedures, as defined in regulatory labeling, typically involve supportive care to manage symptoms and maintain vital functions. In certain cases, measures to reduce drug absorption, such as the use of activated charcoal, or specific antidotes may be recommended, only when explicitly listed in the official prescribing information. Monitoring of key physiological systems, such as cardiac and hepatic function, may be required following the overdose event.

Therapeutic Uses of Reducar

Easing Acute Pain and Physical Discomfort

Reducar is commonly used to help with symptoms related to physical discomfort and inflammatory states, such as minor aches, headache, muscle soreness, and joint tenderness. This medication is applied in addressing symptoms that create noticeable physiological strain, specifically elevated body temperature or fever. It is generally applied in situations where additional symptomatic support is needed for temporary pain and fever, relevant in conditions associated with acute episodes like the common cold or flu.

This class of medication contributes to improved comfort during periods of heightened symptoms. The medication is relevant for easing symptoms that may interfere with daily functioning.

Quick Fact: Reducar is relevant for easing acute pain, discomfort, and fever.

“Reducar supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.” This supportive relief may help patients cope more steadily with symptom fluctuations and contributes to maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of common pain relievers

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Patients 12 years of age and older with severe recalcitrant nodular acne that has been unresponsive to conventional therapy.
  • Women of childbearing potential who strictly comply with all requirements of the mandated Pregnancy Prevention Programme (e.g., iPLEDGE REMS).

Populations for whom use is contraindicated:

  • Pregnant women or women who may become pregnant (due to extremely high risk of severe birth defects).
  • Women who are breastfeeding or nursing.
  • Patients with known Hypersensitivity to the medicine or its components.
  • Patients with Hepatic Insufficiency (liver impairment) or excessively elevated blood lipid values.
  • Patients receiving concomitant treatment with tetracyclines.

Age-related eligibility rules:

  • The medicine is not recommended for children under 12 years of age or for prepubertal acne.

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligibility profile by establishing absolute prohibitions based on reproductive status and pre-existing conditions. This framework strictly restricts use to a narrowly defined population, primarily patients over 12 years old who meet the severe, resistant acne indication, provided they do not possess any specified contraindications related to organ function or concomitant medication. The regulatory profile uses definitive classifications like "contraindicated" and "not recommended" to classify non-eligible groups.

What should I know about interactions with other medicines?

Reducar’s interaction profile is defined by specific restrictions and mandatory administration requirements documented in regulatory labeling.

Documented Drug and Substance Interactions

Co-administration is strictly restricted for several substance classes due to the risk of significant interaction effects.

  • Tetracycline antibiotics (e.g., minocycline, doxycycline) are contraindicated due to the documented risk of inducing Intracranial Hypertension.
  • The co-administration of Vitamin A or Vitamin A supplements is prohibited because of the potential for additive toxic effects, increasing the risk of Hypervitaminosis A.
  • The use of micro-dosed progestin preparations (progestin-only oral contraceptives) is contraindicated, as the drug interferes with the action of these agents, resulting in reduced contraceptive effectiveness.
  • Phenytoin and Systemic Corticosteroids require caution upon co-administration due to the potential for additive pharmacodynamic effects on bone loss. Concomitant topical use of keratolytic or exfoliative anti-acne agents is restricted due to the risk of additive local irritation.

Metabolic and Procedural Constraints

The active ingredient is metabolized by several CYP450 isoenzymes, including CYP2C8, CYP2C9, CYP3A4, and CYP2B6. Reducar exhibits a critical pharmacokinetic dependence on food; regulatory labeling requires the medication to be administered with a meal to ensure proper systemic absorption and adequate plasma exposure (AUC and Cmax). Herbal products, such as St. John's Wort, may reduce the efficacy of hormonal contraceptives, which must be considered due to the required use of reliable contraception. Furthermore, the drug is officially contraindicated in hepatic insufficiency due to the risk of increased systemic exposure. Procedural restrictions include a mandatory period of one month after therapy cessation during which blood donation must be avoided.

Mechanism of Action

Molecular Reprogramming and Sebaceous Gland Atrophy

Reducar's mechanism is driven by its active metabolite acting as an agonist on nuclear Retinoic Acid Receptors (RARs), primarily RAR-gamma. This molecular binding triggers transcriptional regulation, leading to the apoptosis (programmed cell death) of the oil-producing sebocyte cells . The resulting physiological effect is the physical involution and shrinking of the sebaceous glands, causing a substantial reduction in sebum output.


Follicular Normalization and Anti-Inflammatory Cascades

The retinoid action also modulates the differentiation and shedding of follicular skin cells, which normalizes keratinization to prevent follicular obstruction. Concurrently, the molecule exerts an intrinsic anti-inflammatory effect by suppressing pro-inflammatory mediators. These dual cascades alters the follicular ecosystem: the resulting lack of sebum removes the primary nutrient source for follicular bacteria, while anti-inflammatory action decreases local inflammation.

Dosage and Administration Information

How to Use Reducar

The administration of Reducar is structured as a defined, systemic course taken through the oral route in the form of soft gel capsules. Instructions for use require the capsule to be swallowed whole with fluid and not be crushed or chewed. A key instruction for proper use involves the timing of administration: the dose must be taken with a meal, which is necessary for the medication's optimal systemic absorption and bioavailability.

The standard adult daily dosage is determined by body weight, typically initiated at 0.5 mg per kilogram per day (0.5 mg/kg/day) and adjusted within a range that may reach 1.0 mg/kg/day. This daily amount is usually administered either once daily or divided into two separate doses. For specific populations, such as those with severe renal impairment, the starting dose is required to be lowered (e.g., to 10 mg per day).

Treatment constitutes a fixed course, generally lasting 16 to 24 weeks. The primary objective is to reach a total cumulative dose between 120 mg/kg and 150 mg/kg over the entire duration, which defines the planned end of the treatment cycle. If a dose is missed, guidance generally advises taking the next dose at the regularly scheduled time, rather than attempting to double the subsequent dose. Retreatment is permissible only after a pause of at least two months has passed following the completion of the initial course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Reducar (Isotretinoin)

Evidence for Use in Severe Recalcitrant Nodular/Cystic Acne

The clinical evaluation of Reducar for its primary regulated purpose, severe nodular or cystic acne that has not responded to other treatments, is supported by research involving various study types. These include Randomized Controlled Trials (RCTs), where people are assigned by chance to different treatment groups, as well as Systematic Reviews that analyze and combine the findings from multiple trials. Long-term observational studies have also been applied in research contexts to track results over extended periods.

Researchers were primarily interested in outcomes related to changes in inflammatory and non-inflammatory lesion counts, tracking how these symptoms changed over time in the studied populations. These studies often involved adolescents (age 12 and older) and adults who had documented failure to respond to prior conventional therapy. Findings describe patterns observed in these studies, reporting measurements of change during the study period, including measurements related to clinical change status in some cohorts. Evidence contributes to the broader understanding of symptom patterns in this severe condition.


Evidence for Use in Moderate Acne Resistant to Standard Therapy

Reducar was also evaluated in studies exploring its use in patients with moderate acne when their condition proved resistant to standard approaches, such as antibiotics or topical treatments. Research scenarios included short-term Randomized Controlled Trials and systematic reviews that aimed to compare the outcomes associated with this medicine against alternative treatments.

Studies primarily monitored changes in inflammatory lesion count and assessed the degree of overall acne improvement achieved in the observed populations. Findings indicate that outcomes related to physiological change were monitored over defined time intervals, typically 16 to 24 weeks. The evidence base here is often drawn from studies using lower-dose or intermittent treatment regimens that research examined as an alternative approach for this patient group.


Long-Term Research and the Durability of Response

A significant focus of the research has been on the durability of the initial response after the medicine is stopped. Long-term observational research explored the frequency of relapse (acne recurrence) over time. This research monitored patients for extended periods, sometimes for up to three years post-treatment.

Studies explored the patterns of change observed, which provides context regarding patterns of change observed over extended time. Findings describe group patterns related to how symptoms evolved in the observed populations, and this evidence contributes to the overall understanding of acne relapse patterns.

However, there is limited information for long-term outcomes regarding the optimal dose and treatment duration needed to minimize the possibility of relapse. Specifically, the relationship between the cumulative dose a patient receives and the prevention of long-term relapse is not fully established, and research is ongoing in this area.

Key Studies & References

  1. Isotretinoin: The truth about safety, side effects, and skin care (American Academy of Dermatology Guidance)

Frequently Asked Questions (FAQ)

Common questions about Reducar (FAQ)

Q: Is Reducar the same type of medication as Accutane, or is it different?

A: Reducar and Accutane contain the exact same active ingredient: isotretinoin, which is chemically known as 13-cis-Retinoic Acid. Accutane was a recognized brand name for this medication, and Reducar is another brand name for the same drug. Both are systemic retinoids used for severe acne.


Q: What are the most common side effects people experience when taking Reducar?

A: Regulatory documents list the most common adverse reactions as dry lips (known as cheilitis), dry skin, back pain, and joint pain (arthralgia). These effects are categorized as 'very common,' meaning they are expected to occur in a significant number of patients, often 1 out of 10 or more.


Q: What are the serious but less common side effects associated with Reducar?

A: Official product information documents describe several serious adverse reactions affecting various body systems. These include psychiatric disorders, such as new-onset or worsening depression and suicidal thoughts. Other serious, though less common, risks include Pseudotumor Cerebri (a neurological condition), Inflammatory Bowel Disease (IBD), and severe skin reactions like Stevens-Johnson syndrome (SJS). Psychiatric disorders require immediate discussion with a healthcare provider if they occur.


Q: Does Reducar affect cholesterol or liver enzyme levels that require monitoring?

A: Yes, official safety information states that the medication can affect the levels of lipids (fats) and liver enzymes in the blood. For this reason, laboratory tests, including a fasting lipid profile and liver function tests, are typically completed prior to and sometimes during the course of use.


Q: What kind of blood tests are typically done while on Reducar?

A: Due to the potential effects on the body's systems, blood tests are typically conducted to monitor health markers. These laboratory tests generally include a fasting lipid profile to check triglyceride and cholesterol levels, as well as liver function tests.


Q: How long does Reducar stay in the body after the last dose?

A: While the exact time for full elimination varies, official regulatory guidance mandates a critical safety period. Specifically, patients must not donate blood for one full month following the last dose to prevent the medicine from being transferred to a pregnant recipient.


Q: How does Reducar affect the oil production in the skin?

A: The medicine is highly effective at reducing the skin's oil production. It works by causing the oil-producing sebaceous glands to profoundly shrink, which significantly decreases the amount of sebum (oil) output onto the skin.


Q: Is it normal to experience very dry skin and lips while on Reducar?

A: Yes, regulatory documents list dry skin and dry lips (cheilitis) as very common adverse reactions. This is an expected outcome of the drug’s primary action of reducing oil gland size and activity, and it is frequently experienced by patients.


Q: Are eye dryness or vision changes a common side effect of Reducar?

A: Dry eyes are a common side effect documented in official product information. Additionally, decreased night vision has been reported, and this effect may persist after the treatment is stopped. Vision changes, if experienced, are typically required to be assessed by an ophthalmologist.


Q: Why do some people experience a 'purging' or initial worsening of acne on Reducar?

A: Official safety documents recognize that an initial temporary worsening of acne, sometimes referred to as a 'purge' or flare-up, is a documented side effect. This is more likely to occur if the medication is started at a higher dosage.


Q: Can Reducar be used for types of acne that are not severe or nodular?

A: The primary and official regulated use of the medication is for severe recalcitrant nodular or cystic acne that has not responded to other forms of treatment. However, research has also explored its use in moderate acne that has proven resistant to standard therapy.


Q: Why are there special safety programs, like iPLEDGE, for Reducar prescriptions?

A: The mandatory safety programs, such as iPLEDGE in the U.S., are required because the drug carries an absolute and predictable risk of causing severe birth defects (teratogenicity) if taken during pregnancy. These programs ensure strict adherence to required pregnancy prevention steps.


Q: Is Reducar related to naturally occurring vitamins in the body?

A: Yes, the active ingredient in Reducar, isotretinoin, is classified as a retinoid. This means it is a synthetic derivative, or man-made version, of Vitamin A.


Q: Can men use Reducar without any specific safety programs or restrictions?

A: Men who use the medication are not required to follow the mandatory pregnancy prevention steps associated with the safety programs (such as routine pregnancy testing). However, they must agree not to share the medication with anyone or donate blood.


Q: Can Reducar be used for conditions other than severe acne?

A: The officially regulated and primary indication for Reducar is strictly defined as the treatment of severe recalcitrant nodular acne.


Q: Is it true that Reducar can make the skin more fragile or prone to tearing?

A: Official warnings note that the medication can result in dry and fragile skin. Because of this, patients are advised to avoid certain cosmetic procedures such as waxing, dermabrasion, and laser procedures during and for a period after treatment due to the increased risk of scarring or adverse skin reactions.


Q: What is the risk of hair thinning or loss while taking Reducar?

A: Official adverse reaction lists categorize hair loss, or alopecia, as a common side effect of the medication.


Q: Is it normal to feel a bit more tired or fatigued at the start of Reducar treatment?

A: Regulatory documents have reported the general feeling of discomfort, illness, or uneasiness known as malaise. Severe or concerning symptoms of fatigue are typically advised to be reviewed by a healthcare provider.


Q: Can Reducar increase the risk of getting sunburned?

A: Yes, the product labeling indicates that Reducar can cause photosensitivity. This means it increases the skin's sensitivity to the sun, raising the risk of severe sunburn. Regulatory documents indicate that protective measures, such as minimizing sun exposure and using sunscreen, are required.


Q: Is Reducar effective for body acne, such as on the back and chest?

A: The medication is approved for severe recalcitrant nodular acne, which is a systemic condition that can affect the back and chest. While specific studies on body-only acne are not detailed in the label, the treatment is designed to work internally throughout the body.


Q: Can Reducar affect a person's ability to drive at night?

A: Because the drug is associated with a decrease in night vision, official warnings advise that patients should not operate a vehicle at night until they are certain their vision has not been affected.


Q: Do all forms or brands of Reducar work the exact same way?

A: Reducar and other brands contain the same active ingredient, but different formulations or brands of isotretinoin may have different bioavailability. This means the way the body absorbs the medicine can vary, and different dosages might be required for different products.


Q: Does taking Reducar mean I have to stop wearing contact lenses?

A: The medication commonly causes dry eyes, which can sometimes lead to contact lens intolerance. Patients who wear contact lenses should be aware of this common side effect and may need to temporarily adjust their use.


Q: Can Reducar affect bone density or growth plates in teenagers?

A: Official regulatory information includes warnings about musculoskeletal abnormalities. These may include a decrease in bone mineral density and, in adolescents, premature closure of the growth plates, which is a sign that long-bone growth has stopped.


Q: Are mood changes or feelings of depression reported as a side effect of Reducar?

A: Yes, serious adverse reactions documented in the labeling include psychiatric disorders such as new-onset or worsening depression, psychosis, and suicidal thoughts. Any new or worsening psychological symptoms are typically required to be reviewed immediately by a healthcare provider.


Q: Does Reducar cause joint or muscle pain, and if so, how is it managed?

A: Joint pain (arthralgia) and back pain are categorized as very common side effects. While management of pain is a clinical decision between the patient and prescriber, the pain is generally known to be reversible once the medication is stopped.


Q: Is a follow-up course of Reducar ever necessary after the initial treatment is complete?

A: According to official dosage and administration instructions, a second course of treatment is permitted. If retreatment is considered necessary, it is only allowed after a period of at least two months has passed since the completion of the first course.


Q: What is the clinical significance of reaching the total cumulative dose target for Reducar?

A: The total cumulative dose is an established objective for the fixed treatment course. However, regulatory documents state that the relationship between this total dose and the prevention of long-term relapse in all patients is not fully established, and this area remains a focus of ongoing research.


Q: Can alcohol consumption be dangerous while taking Reducar?

A: It is advised to limit or avoid alcohol consumption while on this medication. This is because alcohol can increase the risk of elevated triglycerides and liver damage, which are effects that the medication itself can also potentially cause.

How should Reducar be stored and disposed of?

Storage and Disposal Requirements for Reducar (Isotretinoin)

Reducar (Isotretinoin) must be stored under specific environmental and container conditions as mandated by official regulatory labeling.

Storage Conditions

The medicine requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be kept in the original, tightly closed container and protected from light and moisture; it must not be frozen. All medicine must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Reducar should be disposed of via a medicine take-back program. If a program is unavailable, follow the official guidance of mixing the product with an undesirable substance (such as used coffee grounds) before discarding in a sealed container in household trash. Do not flush Reducar down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reducar found in:

A-Z Index: